Russia, Kazakhstan reach agreements on anti-COVID vaccine production

Business Materials 5 December 2020 13:42 (UTC +04:00)
Russia, Kazakhstan reach agreements on anti-COVID vaccine production

BAKU, Azerbaijan, Dec. 5

BY Nargiz Sadikhova - Trend:

The Russian Direct Investment Fund (RDIF) and Kazakhstan’s Ministry of Healthcare reached a cooperation agreement designed to facilitate the registration, production and distribution of the world’s first registered vaccine against coronavirus - Sputnik V, Trend reports citing RDIF.

Kirill Dmitriev, CEO of RDIF, and Alexey Tsoy, Minister of Health of Kazakhstan, took part in the signing ceremony on Dec.4.

Upon obtaining the regulatory approval, the production technology and the materials required for the production of 2 million doses of the vaccine will be transferred to Kazakhstan.

Currently, Phase III clinical trials have approval and are ongoing in Belarus, the UAE, Venezuela and a number of other countries, as well as Phase II-III being underway in India.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said that the agreement between RDIF and Kazakhstan will help the country's population obtain access to a coronavirus vaccine with an efficacy of more than 91 percent, created using a proven and well-studied platform of human adenovirus vectors.

“The production of the Sputnik V vaccine, which will soon be launched in Kazakhstan, will reduce logistical costs and ensure the quick supply of the vaccine to clinics. Furthermore, the exchange of technological, scientific and medical experience and best practices between our countries will increase,” he said.

Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors.


Follow the author on Twitter: @nargiz_sadikh